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 Abstract 
Background  
Transient elastography is a non-invasive tool which can stratify patients at risk of chronic 
liver disease. However, a raised body mass index has been independently associated with a 
failed or unreliable examination.  
 
Objective 
 
To analyse the performance of two probes (M/XL) on a portable transient elastography 
device within an obese community population.  
 
Method 
Prospective study with recruitment from a primary care practice. Patients identified with a 
risk factor for chronic liver disease were invited to a community based risk stratification 
pathway for transient elastography readings with both probes. A threshold of ≥8.0kPa 
defined elevated liver stiffness.  
 
Results 
477 patients attended the pathway. 21% of patients had no valid measurements with the M 
probe. There was a significant difference between the probes in the proportion achieving 
≥10 valid readings (M vs XL probe: 66.2% vs 90.2%; p = <0.001) and in their reliability (M vs 
XL probe: 77.4% vs 98.5%; p= 0.028). Unreliable readings with the M probe increased as the 
body mass index increased. The XL probe re-stratified 5.2% of patients to have a normal 
reading.  
 Conclusion 
The XL probe on a portable device significantly improves the applicability of transient 
elastography within a community based risk stratification pathway.  
 
Key Summary 
 
Summarise established knowledge 
1. Transient elastography (TE) is an extensively validated diagnostic tool for stratifying the 
severity of liver disease. 
2.  However, a raised body mass index has been independently associated with a failed or 
unreliable examination, a potential limitation when using transient elastography in a 
community based risk stratification pathway. 
3. The XL probe has been developed specifically for obese patients and with it now 
available on the portable device this could increase the applicability of transient 
elastography as a risk stratification tool.  
4. Considering its increasing utilisation in clinical care, there remains a paucity of data on 
the relationship between the M and XL probe when used on the same patient.   
 
Significant/ new findings 
 
1. This is the first study which has demonstrated the feasibility and success of using both 
probes in the community within a risk stratification pathway.  
2. Use of the XL probe significantly increased the number of valid (M vs XL probe: 66.2% vs 
90.2%) and reliable readings (M vs XL probe: 77.4% vs 98.5%) that were obtained. 
3. Use of the correct probe is essential to ensure the patient is risk stratified correctly. The 
XL probe re-stratified 5.2% of patients to have a normal TE reading according to our 
definition for clinically significant liver disease.  
4. Within a risk stratification pathway, the XL probe is not an optional extra, but a necessity 
in a population setting where a raised BMI is becoming routine. 
 
  
 Introduction 
 
Chronic liver disease (CLD) has risen up the public health agenda due to increasing mortality 
rates and the preventable burden of disease within the general population caused in the 
majority by lifestyle related risk factors (1).  
 
Case finding strategies to tackle these issues have been suggested (2, 3) but are not 
routinely implemented. Yet, use of non-invasive tests such as transient elastography (TE) as 
a risk stratification tool for liver disease have previously been demonstrated to be successful 
(4, 5). Advantages of TE include its ease of use, provision of timely results, diagnostic 
accuracy and that it is non-invasive. The convenience of a portable machine also allows risk 
stratification to occur within the community rather than a hospital setting (6).  
 
However, a raised body mass index (BMI) has been independently associated with a failed 
or unreliable TE examination using the standard ‘M’ probe (7-9) with successful readings 
reported in only 75% of obese patients (BMI ≥ 30kg/m2) (10). A potential limitation when 
using TE in a risk stratification pathway. This is concerning given the increasing proportion of 
the general population who are overweight (65% of men and 58% of women in England 
(11)). The XL probe has been developed specifically for obese patients and with it now 
available on the portable device this could increase the applicability of TE within a risk 
stratification pathway.   
 
The aim of this study was to analyse the performance of the M and XL TE probes among 
those with a BMI ≥ 28kg/m2 within a risk stratification pathway based in the community.  
 
Methods 
 
Study setting and population 
 
This is a prospective study with recruitment from a primary care practice in Leicester, 
England. The study ran from January 2015 until March 2016. Local regulatory approval was 
obtained on 10th April 2013 from the Leicester Research Ethics Committee (13/EM/0123) 
and written informed consent was gained from each patient included in the study. The 
study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as 
reflected in a prior approval by the institution's human research committee. The study has 
been registered on the ClinicalTrials.gov website (NCT02037867) 
 
Clinical, anthropometric and biochemical data was obtained from the electronic primary 
care records (SystmOne, TPP, UK) within which data is stored as searchable numerical values 
and prospectively coded ‘Read codes’.  
 
Recruitment occurred via an invitation to attend a community based risk stratification 
pathway for CLD which has been previously described (6). Patients were initially identified 
from the electronic primary care records. Adults (≥ 18 years) with one or more lifestyle 
related risk factors for CLD at the start of the study were invited. These included: 
Commented [RH1]: A declaration of the study 
registered on a public clinical trials registry 
1. Hazardous alcohol use – defined as >14 units/week for women and >21 units/week 
for men, or an AUDIT questionnaire score ≥ 8 (12), or presence of a Read code for 
alcohol misuse.  
2. Type 2 diabetes  - presence of a Read code related to the diagnosis 
3. BMI ≥28.0 kg/m2 – presence of a numerical value recorded within the past 5 years.  
A lower BMI cut off for obesity (≥28.0 kg/m2) was agreed a priori for all patients 
included within the study due to the increased prevalence of people with Asian 
ethnicity in this population. This is in accordance with the World Health Organisation 
(13) who recommend different cut off points for the Asian population due to a 
higher risk of type 2 diabetes and cardiovascular disease at a lower BMI compared to 
European populations. A lower cut off ensured that patients of Asian ethnicity whose 
BMI was lower than the traditional cut off for obesity (30.0 kg/m2) but who were still 
at high risk of CLD were invited to attend.   
 
Patients meeting any of the following criteria were ineligible and not invited to attend the 
risk stratification pathway: 1. Contraindication to undertaking a TE reading (e.g. pregnancy, 
implantable cardiac device) 2. Known diagnosis of CLD 3. Known malignancy or other 
terminal illness 4. Patients unable to consent to investigation or housebound and unable to 
attend.  
 
Transient elastography 
TE is a non-invasive diagnostic test which calculates the degree of liver stiffness by 
propagation of an elastic shear wave. Correlation between its results and stages of liver 
fibrosis has been extensively evaluated and validated in all major aetiologies of CLD (14). 
The TE device can be either static or portable but until recently the XL probe has only been 
available with the static device.  Three experienced operators performed all the TE 
examinations as per the manufacturer’s recommendations and had completed >100 
examinations prior to the study using the portable FibroScan® 402 device (Echosens, Paris). 
The technique for obtaining a TE reading and the differences between the probes has been 
previously described (15, 16). Ten valid measurements were collected with both probes with 
the median value reported as the liver stiffness measurement in kilopascals (kPa). 
Examinations unable to record any valid readings were deemed technical failures. As an 
indicator of variability the ratio of the interquartile range of the liver stiffness to the median 
value (IQR/M) was also recorded. Examinations were compared to the reliability criteria 
outlined by Boursier et al (17) and recommended by the manufacturer. To avoid confusion 
all examinations which are ‘very reliable’ or ‘reliable’ will be referred to in the subsequent 
text as reliable.  
 
A TE reading was attempted with both probes for all patients with a BMI ≥28.0 kg/m2. A 
threshold of ≥8.0kPa was agreed a priori to define elevated liver stiffness consistent with 
clinically significant liver disease. This threshold has been used within other community 
based screening programmes (4) and has been demonstrated to have a high negative 
predictive value for advanced fibrosis (10).   
 
Statistical methods 
 
Statistical analysis was completed using Stata version 14.2 (StataCorp LP). Baseline 
characteristics of the study cohort are presented as numbers (percentage) if categorical 
data or medians (IQR) for non-normally distributed continuous data. A comparison of the 
performance of both probes was made using the chi squared test and the Wilcoxon signed 
rank test for categorical and non-normally distributed continuous data respectively.  
The difference in the number of reliable and unreliable readings between the two probes 
using the criteria outlined by Boursier (17) was compared using the chi squared test. 
Readings between the two probes were also compared in accordance with how this would 
affect risk stratification. A patient was considered to be re-stratified if the XL probe reading 
was <8kPa when the M probe reading had been ≥8kPa (in line with our definition of 
clinically significant liver disease). Correlation between the liver stiffness measurements 
obtained by both probes was calculated and a linear regression analysis was completed to 
further characterise this relationship. Multivariable regression analysis was carried out to 
estimate the effect of potential confounding variables. Agreement between the probes was 
further analysed using a Bland-Altman plot. To identify variables independently associated 
with re-stratification univariate and multivariate logistic regression models including the 
covariates age, gender, BMI, hypertension, hypercholesterolaemia, the reliability of the M 
probe reading, Type 2 diabetes and Hazardous alcohol use as a risk factor were conducted.  
 
 
Results 
 
Patient characteristics 
 
The primary care practice had a total adult population of 4150 with 1167 patients identified 
to have at least one risk factor and eligible to be invited to attend the risk stratification 
pathway. Of these, 720 patients attended of which 477 had a BMI ≥28.0 kg/m2 and had 
attempted TE readings with both probes (Patient characteristics outlined in table 1). Fifty 
percent of the patients were male and the median age was 58 years (IQR 47-68). The 
majority of the patients were white (72.5%) although this was lower than the general 
population (87.2% in the UK) due to the high percentage of patients with Asian ethnicity 
(24.6%) in the community in which the risk stratification pathway was implemented. 
Seventy three percent of the cohort had a BMI ≥28.0 kg/m2 as their only risk factor whilst 
10.9% and 15.4% also had hazardous alcohol use or type 2 diabetes as an additional risk 
factor; 2.1% of patients had all three risk factors. The median BMI was 31.4 (IQR 29.4-34.7).  
 
Reliability of the probes 
 
The XL probe increased the number of valid TE readings (Table 2); 21% of the patients had 
no valid measurements with the M probe. There was a significant difference in the 
proportion who had ≥10 valid readings between the M and XL probes (66.2% vs 90.2%; p 
<0.001); 76% of the patients with <10 valid readings with the M probe had ≥10 readings 
with the XL probe.  
 
A significant difference was also seen in the reliability with >96% of patients with an 
unreliable M probe reading obtaining a reliable XL probe reading (Table 3). According to the 
reliability criteria (17) only 0.84% of the patients did not obtain a reliable reading with either 
probe (Table 3). The number of reliable measurements increased with the XL probe and a 
significant difference was observed between the two probes (M vs XL probe: 77.4% vs 
98.5%; p= 0.028). The number of unreliable readings increased with the M probe as the BMI 
increased whilst with the XL probe the number of unreliable readings remained low across 
all BMI categories.  
 
The TE readings between the probes were highly correlated (R2 0.78, p value <0.001) (Figure 
1). A Bland-Altman plot (Figure 2) demonstrated this and revealed a larger difference at 
higher mean values (Pitman’s test of difference in variance: r=0.656, p value = <0.001). In 
multivariable analysis no appreciable confounding of this relationship was found with any of 
the studied variables (BMI, Gender, Ethnicity, Age, Type 2 diabetes as a risk factor, 
Hazardous alcohol use as a risk factor). In general, the XL probe readings were lower than 
those obtained with the M probe with linear regression analysis returning the following 
estimate: XL = (0.59 x M) + 1.73.  
 
Use of both probes within the community risk stratification pathway  
 
The XL probe ensured 21% of patients obtained a TE reading who otherwise would have 
been deemed a technical failure if only the M probe was available. The XL probe also re-
stratified 5.2% of patients to have a normal TE reading according to our definition for 
clinically significant liver disease (Table 4). The percentage of patients re-stratified increased 
as the BMI increased. BMI was the only variable in a multivariate logistic regression which 
was significantly associated with re-stratification. For every 1kg/m2 increase in BMI the odds 
of being re-stratified increase by 19% (Table 5). 
  
Discussion 
 
Key findings 
Within a risk stratification pathway, an ideal tool would reliably identify patients at high risk 
of disease and exclude those who are normal.  However, as we have demonstrated use of TE 
with only the M probe as a risk stratification tool in an obese cohort could potentially lead 
to a large number of patients with an invalid or unreliable TE reading. 
 
Despite 93.1% of patients who had a TE reading with both probes being risk stratified 
equivalently, 1 in 5 patients within this obese community cohort had no valid readings with 
the M probe. Use of the XL probe significantly improved the number of valid and reliable TE 
readings that were obtained.  
 
Linear regression analysis suggests there is a good correlation between the probes with the 
readings from the XL probe relating to that of the M probe in line with the equation (XL = 
(0.59x M) + 1.73). The XL probe readings are lower than the M probe which is consistent 
with other findings in the literature (16, 18). The Bland-Altman plot demonstrates this 
difference when using both probes in the same individual and that this difference is larger 
the greater the mean reading.  
 
 
Strengths and limitations 
 
Whilst other studies (16, 19) have compared both probes in a hospital setting we have 
demonstrated the feasibility of using both probes in a community risk stratification 
pathway. Ten valid measurements were obtained in 66.3% of patients using the M probe 
and in 90.2% with the XL probe. This performance compares favourably to other studies (16, 
19) despite being used in a community rather than a hospital setting.  
 
The percentage of reliable readings is lower than other studies which have risk stratified 
using TE in the community (Baba et al (20): 98.3%; You et al (21) 97%). This is likely due to 
the increased number of patients with obesity in our cohort compared to the unselected 
general population used within these studies. This highlights the importance of having 
access to the XL probe in order to maximise the numbers of patients who could be risk 
stratified.   
 
A limitation is the inability to comment on the diagnostic performance of TE within this 
population and healthcare setting. We were unable to compare the two TE probe readings 
against histological findings although a liver biopsy does have its own documented 
limitations (22). Myers et al (16) analysed the performance of both TE probes against 
histological outcomes in an overweight cohort and identified optimal liver stiffness cut offs 
with the M probe (≥7.8kPa) and the XL probe (≥6.4kPa) for diagnosing ≥ F2 fibrosis. It is 
worth noting that according to our equation, conversion of an M probe cut off of 7.8kPa 
yields an XL probe cut off of 6.3kPa which is remarkably close to the value derived by Myers 
et al.  
 
However, it has been reported that the disparity between the two probes is eliminated 
when the M probe is re-calibrated to measure an equivalent depth to the XL probe (16). 
Similarly, when the stiffness is made homogeneous using phantom liver models the 
difference between the probe readings disappears (16). Histological specimens demonstrate 
a greater amount of fibrous tissue around the subcapsular region which can be out of 
proportion to the remainder of the parenchyma (23). This suggests that the lower readings 
observed with the XL probe may be due to a deeper area of the liver being scanned. A 
recent update of the device automatically selects the “appropriate” probe based on skin 
capsular distance (SCD). Our data shows the difference in readings which might occur if this 
guidance is not followed and consequently the potential error in risk stratification of 
patients (24).  Thus choosing the correct probe is not for the sole reason of obtaining a 
reliable scan. Though our linear regression equation shows a clear relationship numerically 
between results from the two probes, it does not imply one probe can be substituted for 
another. The relationship between the probes at higher stages of fibrosis may differ, as 
highlighted by the Bland Altman plot.  
 
At present, it is assumed that the same liver stiffness cut off can be used if the “appropriate” 
probe has been chosen. A validation study of the XL probe is required to ensure this 
assumption is correct and that the liver stiffness measurement obtained is reliable and 
correlates with the histological diagnosis. As we were unable to measure SCD and did not 
have any histological comparisons we are unable to validate the XL probe in this study but 
are aware of emerging evidence.  
 
Relevance to clinical practice 
 
There is an urgent need to tackle the growing epidemic of CLD and actively identity those 
patients who are at increased risk of liver related disease and death (25). With new 
guidelines recommending screening for patients at high risk of CLD (3) tools which are 
accessible and easily utilised are imperative. Our results suggest that a valid and reliable M 
probe reading is unlikely to underestimate the degree of liver fibrosis and consequently 
should not mis-stratify patients who have undiagnosed CLD. This is supported by the close 
correlation observed between the results from the two probes. However, access to the M 
probe alone would limit the applicability of TE within a community based risk stratification 
pathway. The adjunct of the XL probe with the portable device is an important advance to 
this technology to achieve a non-invasive test which can be universally applied to all 
patients at risk (26).  
 
Whilst the added cost to a health care commissioner may be of concern this must be 
weighed up against the cost of a false positive result, a screening failure or even the cost to 
the health care system as a whole if the patient was to remain undiagnosed. Health 
economic analyses of proposed case finding strategies would be useful to determine the 
added economic value of having the XL probe available on a portable TE device.  
 
Even if the XL probe is accessible, there still remains uncertainty over when it should be 
utilised to ensure a reliable reading is obtained. The manufacturer recommends measuring 
the SCD to determine which probe to use but this is not always possible in a community 
setting. This was indeed the case in our current study. Other studies have demonstrated a 
patient’s BMI to be a reasonable surrogate for SCD. Our results demonstrate that 25% of 
patients with a BMI>30 kg/m2 had an unreliable reading with the M probe. This therefore 
could be a practical threshold in which the XL probe should be considered ahead of the M 
probe. Alternatively, the M probe may soon become redundant if the XL probe is able to 
provide more reliable readings in a general population who are increasingly overweight and 
at risk of CLD.   
 
Lastly, assuming that the same liver stiffness cut off can be used for both probes, 
identification of the most appropriate probe would also ensure that the patient is risk 
stratified correctly. Within this study cohort alone, 1 in 20 patients may have been risk 
stratified incorrectly. Importantly in the multivariable logistic regression, BMI was the only 
variable which was significantly associated with re-stratification. Thus, the XL probe is now 
not an optional extra but a necessity in a population setting where obesity is becoming 
routine. 
 
Conclusion 
 
A reliable and valid M probe reading is unlikely to mis-stratify patients within a community 
based risk stratification pathway. The addition of the XL probe optimises the applicability of 
TE within a case finding strategy by significantly increasing the number of patients with 
reliable readings and ensuring they are risk stratified correctly, particularly in an obese 
cohort. Clinicians should be aware of the additional benefits the XL probe can offer in a 
population where obesity prevalence is increasing.  
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